The Leukemia Research Foundation distributes $1.2 million for blood cancer research projects.
NORTHFIELD, Ill., July 26, 2019 -- The Leukemia Research Foundation is proud to announce $1.2 million in blood cancer research funding for the 2019-2020 funding cycle. Twelve, one-year grants of $100,000 each are awarded through the Hollis Brownstein Research Grants Program for New Investigators.
Congratulations to the following list of grantees.
Stephanie A. Berg, D.O. – Cardinal Bernardin Cancer Center, Loyola Medicine (Maywood, Illinois)
Germline Mutations Predispose to Familial Myeloproliferative Neoplasms
M. Andres Blanco, Ph.D. – University of Pennsylvania School of Veterinary Medicine
Dual Targeting of LSD1 and KAT6A to Induce Therapeutic Differentiation in AML
Hamza Celik, Ph.D. – Washington University School of Medicine (St. Louis, Missouri)
Generation of a Faithful Patient-derived Xenograft Model of Myelofibrosis for
Steven M. Chan, M.D., Ph.D. – Princess Margaret Cancer Centre (Toronto, Canada)
Repurposing Metformin to Prevent Blood Cancers and Cardiovascular Diseases Associated with TET2 Mutation-Driven Clonal Hematopoiesis
Raffaella Di Micco, Ph.D. – Ospedale San Raffaele (Milan, Italy)
Targeting of Epigenetic Drivers of Immune Evasion in Acute Myeloid Leukemia Relapses After Allogeneic HSCT
Daichi Inoue, M.D., Ph.D. – Institute of Biomedical Research and Innovation (IBRI)
(Kobe City, Japan)
Understanding the Role of ZRSR2 Mutations in Myeloid Malignancies
Irum Khan, M.D. – University of Illinois at Chicago (Chicago, Illinois)
Targeting FOXM1 to Improve Treatment Responses in AML
Yongsoo Kim, Ph.D. – VU University (Amsterdam, Netherlands)
A Computational Framework to Model Cellular Interplays in the Tumor Microenvironment of B Cell Lymphoma
Rui Lu, Ph.D. – University of Alabama (Birmingham, Alabama)
A Novel Stemness Program with Epigenetic Dysregulation in Acute Myeloid Leukemia
Michael Milyavsky, Ph.D. – Tel Aviv University (Tel Aviv, Israel)
Harnessing Stemness Reporter to Identify and Target Critical Dependency Genes
in Human Leukemia Stem Cells
Christopher Ott, Ph.D. – Massachusetts General Hospital Cancer Center (Charlestown, Massachusetts)
Deciphering Mechanisms of PAX5 Addiction in Lymphoma
Capucine Van Rechem, Ph.D. – Stanford University School of Medicine (Stanford, California)
Identify New Functions for PRMT5 in B-Cell Lymphoma to Unravel Therapeutic Strategies
“The primary mission of the Leukemia Research Foundation is to fund research into the causes of and cures for blood cancers and providing grants to New Investigators is critically important,” said Leukemia Research Foundation Executive Director Kevin Radelet.
“Each year, federal funding becomes more difficult to secure and New Investigators with fresh, groundbreaking ideas can’t get the funding they need to develop their ideas and the data required for greater funding from the National Institutes of Health (NIH) and other sources. Leukemia Research Foundation funding not only advances blood cancer science but also jumpstarts careers for these scientists,” Radelet said.
Each proposal was thoroughly evaluated and scored using the same scoring system adhered to by the NIH. The Leukemia Research Foundation Medical Advisory Board, led by Patrick J. Stiff, M.D., director of Loyola Medicine's Division of Hematology/Oncology in Maywood, Ill., discussed each project in person that scored in the top half of the preliminary critique. Final recommendations were forwarded to the Leukemia Research Foundation for funding.
The Leukemia Research Foundation has funded more than 500 research projects on five continents since 1946. Funding for the FY 2019-2020 cycle will begin on July 1, 2019. For more information about the Leukemia Research Foundation and its Hollis Brownstein Research Grants Program, visit www.allbloodcancers.org or call 847-424-0600.
About The Leukemia Research Foundation (LRF)
The Leukemia Research Foundation, a CharityNavigator.org 4-Star Charity headquartered in Northfield, Ill., is committed to funding research and providing support to people affected by blood cancers. The Leukemia Research Foundation is dedicated to conquering all blood cancers by funding research into their causes and cures, and enriching the quality of life of those touched by these diseases. For 73 years, thousands of volunteers and 22 current volunteer chapters have helped the Foundation raise more than $80 million to help fund research specifically targeting aspiring, eager, and innovative scientists and physicians around the world, provide patient financial assistance, and offer educational and emotional support for patients and their families.
Leukemia Research Foundation information is available at www.allbloodcancers.org, or by calling 847-424-0600.
For additional information call:
Carl Alston, Director of Communications